SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
NMRA

Neumora Therapeutics, Inc. (NASDAQ:NMRA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.33-$0.01 (-3.78%)
 
Market cap
$63.0M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 15, 2023
Market Cap$63.01M-85.7%
Revenue (ttm)$0
Net Income-$190.43M+19.4%
EPS-$1.06+27.9%
Shares Out188.69M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,059,349
Open$0.34
Previous Close$0.35
Day's Range$0.30 - $0.36
52-Week Range$0.30 - $3.65
Beta3.14
AnalystsBuy
Price Target$4.50(+1247.71%)
Earnings DateMar 29, 2027

About NMRA

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Address
490 Arsenal Way, Watertown, MA, 02472, US
Market Cap
63 million
Employees
60
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$741.23K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From NMRA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-3.78%
5 Days
-21.42%
1 Month
-19.74%
6 Months
-81.95%
1 Year
-85.67%

$NMRA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in NMRA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NMRA's directors and management

Net Shares Purchased by Insiders−500k−250k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NMRA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New NMRA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NMRA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in NMRA

VTIVanguard Morningstar Total Stock Market ETF$994.13K
IWMiShares Russell 2000 ETF$876.27K
VXFVanguard Extended Market ETF$413.49K
IWOiShares Russell 2000 Growth ETF$370.94K
VTWOVanguard Russell 2000 ETF$222.32K
IBBiShares Biotechnology ETF$207.97K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from NMRA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
35

News check: Analyst price target cuts and downward valuation revision dominate coverage, though Guggenheim maintains Buy rating despite cutting target to $8 from $14.

Recent Insider Activity

Buys
0
Sells
13
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.08%
IBBQInvesco Nasdaq Biotechnology ETF0.00%
BIBProShares Ultra Nasdaq Biotechnology0.00%
IBBiShares Biotechnology ETF0.00%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.